Novo Nordisk’s Patent Cliff Isn’t Coming — It’s Already Here, and the Pricing Model Breaks on Impact
Semaglutide's patent expiration isn't a future problem for GLP-1 manufacturers — it's an active restructuring of the global obesity...
Generic Competition